10-Q Filing

CDT EQUITY INC. CIK: 1896212 Q3 2023

Filing Information

Form Type	10-Q
Accession Number	`0001493152-23-042176`
Period End Date	20230930
Filing Date	20231120
Fiscal Year	2023
Fiscal Period	Q3
XBRL Instance	form10-q_htm.xml

Filing Contents

This filing contains the following financial statements:

Balance Sheet 74 Income Statement 60 Cash Flow Statement 96 Stockholders Equity 58

Balance Sheet 74 line items

Line Item	Tag	Value	Unit	Period
Common Stock, Par or Stated Value Per Share	`CommonStockParOrStatedValuePerShare`	$0.00	USD	Point-in-time
Common Stock, Par or Stated Value Per Share	`CommonStockParOrStatedValuePerShare`	$0.00	USD	Point-in-time
Common Stock, Shares Authorized	`CommonStockSharesAuthorized`	400.00M	shares	Point-in-time
Common Stock, Shares Authorized	`CommonStockSharesAuthorized`	250.00M	shares	Point-in-time
Cash and cash equivalents	`CashAndCashEquivalentsAtCarryingValue`	$8.64M	USD	Point-in-time
Common Stock, Shares, Outstanding	`CommonStockSharesOutstanding`	64.63M	shares	Point-in-time
Common Stock, Shares, Outstanding	`CommonStockSharesOutstanding`	72.81M	shares	Point-in-time
Cash and cash equivalents	`CashAndCashEquivalentsAtCarryingValue`	-	USD	Point-in-time
Prepaid expenses and other current assets	`PrepaidExpenseAndOtherAssetsCurrent`	$1.80M	USD	Point-in-time
Preferred stock, par value	`PreferredStockParOrStatedValuePerShare`	$0.00	USD	Point-in-time
Prepaid expenses and other current assets	`PrepaidExpenseAndOtherAssetsCurrent`	-	USD	Point-in-time
Preferred stock, par value	`PreferredStockParOrStatedValuePerShare`	$0.00	USD	Point-in-time
Preferred stock, shares authorized	`PreferredStockSharesAuthorized`	-	shares	Point-in-time
Total current assets	`AssetsCurrent`	-	USD	Point-in-time
Preferred stock, shares authorized	`PreferredStockSharesAuthorized`	1.00M	shares	Point-in-time
Total current assets	`AssetsCurrent`	$10.44M	USD	Point-in-time
Intangible assets - research and development	`IntangibleAssetsNetExcludingGoodwill`	$5.00K	USD	Point-in-time
Preferred stock, shares issued	`PreferredStockSharesIssued`	-	shares	Point-in-time
Intangible assets - research and development	`IntangibleAssetsNetExcludingGoodwill`	$5.00K	USD	Point-in-time
Preferred stock, shares issued	`PreferredStockSharesIssued`	-	shares	Point-in-time
Deposits and other long-term assets	`DepositsAndOtherAssetsNoncurrent`	$1.57M	USD	Point-in-time
Deposits and other long-term assets	`DepositsAndOtherAssetsNoncurrent`	-	USD	Point-in-time
Preferred stock, shares outstanding	`PreferredStockSharesOutstanding`	-	shares	Point-in-time
Preferred stock, shares outstanding	`PreferredStockSharesOutstanding`	-	shares	Point-in-time
Total assets	`Assets`	$5.00K	USD	Point-in-time
Total assets	`Assets`	$12.02M	USD	Point-in-time
Accounts payable	`AccountsPayableCurrent`	-	USD	Point-in-time
Accounts payable	`AccountsPayableCurrent`	$35.00K	USD	Point-in-time
Accrued expenses and other current liabilities	`AccruedExpensesAndOtherLiabilitiesCurrent`	$1.20M	USD	Point-in-time
Accrued expenses and other current liabilities	`AccruedExpensesAndOtherLiabilitiesCurrent`	-	USD	Point-in-time
Accrued professional fees	`AccruedProfessionalFeesCurrent`	$2.25M	USD	Point-in-time
Accrued professional fees	`AccruedProfessionalFeesCurrent`	$1.61M	USD	Point-in-time
Accrued payroll and other current liabilities	`EmployeeRelatedLiabilitiesCurrent`	$33.00K	USD	Point-in-time
Accrued payroll and other current liabilities	`EmployeeRelatedLiabilitiesCurrent`	$338.00K	USD	Point-in-time
Option liability, current portion	`OptionLiabilityCurrent`	-	USD	Point-in-time
Option liability, current portion	`OptionLiabilityCurrent`	$742.00K	USD	Point-in-time
Convertible promissory note payable	`ConvertiblePromissoryNotePayable`	$804.00K	USD	Point-in-time
Convertible promissory note payable	`ConvertiblePromissoryNotePayable`	-	USD	Point-in-time
Notes payable, current portion	`NotesPayableCurrent`	-	USD	Point-in-time
Notes payable, current portion	`NotesPayableCurrent`	$177.00K	USD	Point-in-time
Total current liabilities	`LiabilitiesCurrent`	$4.60M	USD	Point-in-time
Total current liabilities	`LiabilitiesCurrent`	$4.00M	USD	Point-in-time
Convertible notes payable, carried at fair value	`ConvertibleLongTermNotesPayable`	-	USD	Point-in-time
Convertible notes payable, carried at fair value	`ConvertibleLongTermNotesPayable`	$1.83M	USD	Point-in-time
Liability related to the sale of future revenue	`DeferredRevenueNoncurrent`	$4.08M	USD	Point-in-time
Liability related to the sale of future revenue	`DeferredRevenueNoncurrent`	$2.67M	USD	Point-in-time
Notes payable	`NotesPayableNoncurrent`	-	USD	Point-in-time
Notes payable	`NotesPayableNoncurrent`	$175.00K	USD	Point-in-time
Option liability	`OptionLiabilityNonCurrent`	-	USD	Point-in-time
Option liability	`OptionLiabilityNonCurrent`	$1.42M	USD	Point-in-time
Derivative warrant liability	`SharesSubjectToMandatoryRedemptionSettlementTermsFairValueOfShares`	-	USD	Point-in-time
Derivative warrant liability	`SharesSubjectToMandatoryRedemptionSettlementTermsFairValueOfShares`	$92.00K	USD	Point-in-time
Deferred commission payable	`DeferredCommissionPayableNonCurrent`	$5.74M	USD	Point-in-time
Deferred commission payable	`DeferredCommissionPayableNonCurrent`	-	USD	Point-in-time
Total liabilities	`Liabilities`	$13.10M	USD	Point-in-time
Total liabilities	`Liabilities`	$10.09M	USD	Point-in-time
Common stock, par value $0.0001; 250,000,000 shares and 400,000,000 shares authorized at September 30, 2023 and December 31, 2022, respectively, 72,813,776 shares and 64,626,430 shares issued and outstanding at September 30, 2023 and December 31, 2022, respectively	`CommonStockValue`	$7.00K	USD	Point-in-time
Common stock, par value $0.0001; 250,000,000 shares and 400,000,000 shares authorized at September 30, 2023 and December 31, 2022, respectively, 72,813,776 shares and 64,626,430 shares issued and outstanding at September 30, 2023 and December 31, 2022, respectively	`CommonStockValue`	$6.00K	USD	Point-in-time
Preferred stock, par value $0.0001; 1,000,000 shares and nil shares authorized at September 30, 2023 and December 31, 2022, respectively; nil shares issued and outstanding at September 30, 2023 and December 31, 2022	`PreferredStockValue`	-	USD	Point-in-time
Preferred stock, par value $0.0001; 1,000,000 shares and nil shares authorized at September 30, 2023 and December 31, 2022, respectively; nil shares issued and outstanding at September 30, 2023 and December 31, 2022	`PreferredStockValue`	-	USD	Point-in-time
Additional paid-in capital	`AdditionalPaidInCapital`	$11.35M	USD	Point-in-time
Additional paid-in capital	`AdditionalPaidInCapital`	-	USD	Point-in-time
Accumulated deficit	`RetainedEarningsAccumulatedDeficit`	$-13.08M	USD	Point-in-time
Accumulated deficit	`RetainedEarningsAccumulatedDeficit`	$-10.77M	USD	Point-in-time
Accumulated other comprehensive income	`AccumulatedOtherComprehensiveIncomeLossNetOfTax`	$675.00K	USD	Point-in-time
Accumulated other comprehensive income	`AccumulatedOtherComprehensiveIncomeLossNetOfTax`	$639.00K	USD	Point-in-time
Total stockholders deficit	`StockholdersEquity`	$-10.09M	USD	Point-in-time
Total stockholders deficit	`StockholdersEquity`	$-6.14M	USD	Point-in-time
Total stockholders deficit	`StockholdersEquity`	$-15.04M	USD	Point-in-time
Total stockholders deficit	`StockholdersEquity`	$-1.08M	USD	Point-in-time
Total stockholders deficit	`StockholdersEquity`	$-5.94M	USD	Point-in-time
Total stockholders deficit	`StockholdersEquity`	$-6.49M	USD	Point-in-time
Total liabilities and stockholders deficit	`LiabilitiesAndStockholdersEquity`	$12.02M	USD	Point-in-time
Total liabilities and stockholders deficit	`LiabilitiesAndStockholdersEquity`	$5.00K	USD	Point-in-time

Income Statement 60 line items

Line Item	Tag	Value	Unit	Period
Research and development expenses	`ResearchAndDevelopmentExpense`	$38.00K	USD	3 Qtrs
Research and development expenses	`ResearchAndDevelopmentExpense`	-	USD	1 Quarter
Research and development expenses	`ResearchAndDevelopmentExpense`	-	USD	3 Qtrs
Research and development expenses	`ResearchAndDevelopmentExpense`	$38.00K	USD	1 Quarter
General and administrative expenses	`GeneralAndAdministrativeExpense`	$4.37M	USD	3 Qtrs
General and administrative expenses	`GeneralAndAdministrativeExpense`	$775.00K	USD	1 Quarter
General and administrative expenses	`GeneralAndAdministrativeExpense`	$1.07M	USD	1 Quarter
General and administrative expenses	`GeneralAndAdministrativeExpense`	$1.33M	USD	3 Qtrs
Funding expenses	`FundingExpenses`	$120.00K	USD	3 Qtrs
Funding expenses	`FundingExpenses`	-	USD	3 Qtrs
Funding expenses	`FundingExpenses`	$120.00K	USD	1 Quarter
Funding expenses	`FundingExpenses`	-	USD	1 Quarter
Total operating costs and expenses	`OperatingExpenses`	$933.00K	USD	1 Quarter
Total operating costs and expenses	`OperatingExpenses`	$4.37M	USD	3 Qtrs
Total operating costs and expenses	`OperatingExpenses`	$1.49M	USD	3 Qtrs
Total operating costs and expenses	`OperatingExpenses`	$1.07M	USD	1 Quarter
Operating loss	`OperatingIncomeLoss`	$-4.37M	USD	3 Qtrs
Operating loss	`OperatingIncomeLoss`	$-1.07M	USD	1 Quarter
Operating loss	`OperatingIncomeLoss`	$-933.00K	USD	1 Quarter
Operating loss	`OperatingIncomeLoss`	$-1.49M	USD	3 Qtrs
Other income (expense), net	`OtherNonoperatingIncomeExpense`	$2.15M	USD	3 Qtrs
Other income (expense), net	`OtherNonoperatingIncomeExpense`	$-23.00K	USD	1 Quarter
Other income (expense), net	`OtherNonoperatingIncomeExpense`	$3.10M	USD	1 Quarter
Other income (expense), net	`OtherNonoperatingIncomeExpense`	$-330.00K	USD	3 Qtrs
Interest expense, net	`InterestIncomeExpenseNonoperatingNet`	-	USD	3 Qtrs
Interest expense, net	`InterestIncomeExpenseNonoperatingNet`	-	USD	1 Quarter
Interest expense, net	`InterestIncomeExpenseNonoperatingNet`	$-47.00K	USD	1 Quarter
Interest expense, net	`InterestIncomeExpenseNonoperatingNet`	$-92.00K	USD	3 Qtrs
Total other (expense) income, net	`NonoperatingIncomeExpense`	$-330.00K	USD	3 Qtrs
Total other (expense) income, net	`NonoperatingIncomeExpense`	$3.06M	USD	1 Quarter
Total other (expense) income, net	`NonoperatingIncomeExpense`	$2.05M	USD	3 Qtrs
Total other (expense) income, net	`NonoperatingIncomeExpense`	$-23.00K	USD	1 Quarter
Net income (loss)	`NetIncomeLoss`	$-956.00K	USD	1 Quarter
Net income (loss)	`NetIncomeLoss`	$-1.82M	USD	3 Qtrs
Net income (loss)	`NetIncomeLoss`	$1.99M	USD	1 Quarter
Net income (loss)	`NetIncomeLoss`	$-2.31M	USD	3 Qtrs
Basic earnings/(net loss) per share	`EarningsPerShareBasic`	$-0.03	USD	1 Quarter
Basic earnings/(net loss) per share	`EarningsPerShareBasic`	$-0.06	USD	3 Qtrs
Basic earnings/(net loss) per share	`EarningsPerShareBasic`	$-0.04	USD	3 Qtrs
Basic earnings/(net loss) per share	`EarningsPerShareBasic`	$0.03	USD	1 Quarter
Diluted earnings/(net loss) per share	`EarningsPerShareDiluted`	$-0.03	USD	1 Quarter
Diluted earnings/(net loss) per share	`EarningsPerShareDiluted`	-	USD	1 Quarter
Diluted earnings/(net loss) per share	`EarningsPerShareDiluted`	$-0.07	USD	3 Qtrs
Diluted earnings/(net loss) per share	`EarningsPerShareDiluted`	$-0.06	USD	3 Qtrs
Basic weighted-average common shares outstanding	`WeightedAverageNumberOfSharesOutstandingBasic`	64.89M	shares	3 Qtrs
Basic weighted-average common shares outstanding	`WeightedAverageNumberOfSharesOutstandingBasic`	65.41M	shares	1 Quarter
Basic weighted-average common shares outstanding	`WeightedAverageNumberOfSharesOutstandingBasic`	32.31M	shares	1 Quarter
Basic weighted-average common shares outstanding	`WeightedAverageNumberOfSharesOutstandingBasic`	32.31M	shares	3 Qtrs
Diluted weighted-average common shares outstanding	`WeightedAverageNumberOfDilutedSharesOutstanding`	66.13M	shares	1 Quarter
Diluted weighted-average common shares outstanding	`WeightedAverageNumberOfDilutedSharesOutstanding`	32.31M	shares	3 Qtrs
Diluted weighted-average common shares outstanding	`WeightedAverageNumberOfDilutedSharesOutstanding`	32.31M	shares	1 Quarter
Diluted weighted-average common shares outstanding	`WeightedAverageNumberOfDilutedSharesOutstanding`	65.49M	shares	3 Qtrs
Foreign currency translation adjustment	`OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent`	$36.00K	USD	3 Qtrs
Foreign currency translation adjustment	`OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent`	$610.00K	USD	1 Quarter
Foreign currency translation adjustment	`OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent`	$608.00K	USD	1 Quarter
Foreign currency translation adjustment	`OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent`	$1.27M	USD	3 Qtrs
Total comprehensive income (loss)	`ComprehensiveIncomeNetOfTax`	$-348.00K	USD	1 Quarter
Total comprehensive income (loss)	`ComprehensiveIncomeNetOfTax`	$-547.00K	USD	3 Qtrs
Total comprehensive income (loss)	`ComprehensiveIncomeNetOfTax`	$-2.28M	USD	3 Qtrs
Total comprehensive income (loss)	`ComprehensiveIncomeNetOfTax`	$2.60M	USD	1 Quarter

Cash Flow Statement 96 line items

Line Item	Tag	Value	Unit	Period
Net loss	`NetIncomeLoss`	$-956.00K	USD	1 Quarter
Net loss	`NetIncomeLoss`	$-1.82M	USD	3 Qtrs
Net loss	`NetIncomeLoss`	$1.99M	USD	1 Quarter
Net loss	`NetIncomeLoss`	$-2.31M	USD	3 Qtrs
Gain on investment in equity securities	`GainLossOnInvestments`	-	USD	3 Qtrs
Gain on investment in equity securities	`GainLossOnInvestments`	$34.00K	USD	3 Qtrs
(Gain) loss on change in fair value of Cizzle option	`GainLossOnChangeInFairValueOfCizzleOption`	$1.31M	USD	3 Qtrs
(Gain) loss on change in fair value of Cizzle option	`GainLossOnChangeInFairValueOfCizzleOption`	$-216.00K	USD	3 Qtrs
Gain on change in fair value of Vela option	`GainOnChangeInFairValueOfVelaOption`	$748.00K	USD	3 Qtrs
Gain on change in fair value of Vela option	`GainOnChangeInFairValueOfVelaOption`	-	USD	3 Qtrs
Loss on issuance of Vela option	`LossOnIssuanceOfVelaOption`	$1.01M	USD	3 Qtrs
Loss on issuance of Vela option	`LossOnIssuanceOfVelaOption`	-	USD	3 Qtrs
Unrealized foreign exchange loss	`ForeignCurrencyTransactionGainLossUnrealizedAfterTax`	-	USD	3 Qtrs
Unrealized foreign exchange loss	`ForeignCurrencyTransactionGainLossUnrealizedAfterTax`	$-4.00K	USD	3 Qtrs
Change in reserve for related party uncollectible loan	`ForeignCurrencyTransactionGainLossUnrealized`	$118.00K	USD	1 Quarter
Change in reserve for related party uncollectible loan	`ForeignCurrencyTransactionGainLossUnrealized`	$118.00K	USD	1 Quarter
Change in reserve for related party uncollectible loan	`ForeignCurrencyTransactionGainLossUnrealized`	$240.00K	USD	3 Qtrs
Change in reserve for related party uncollectible loan	`ForeignCurrencyTransactionGainLossUnrealized`	-	USD	3 Qtrs
Loss on related party loan forgiveness	`LossOnRelatedPartyLoanForgiveness`	$12.00K	USD	3 Qtrs
Loss on related party loan forgiveness	`LossOnRelatedPartyLoanForgiveness`	-	USD	3 Qtrs
Loss on change in fair value of convertible notes payable	`LossOnChangeInFairValueOfConvertibleNotesPayable`	$148.00K	USD	3 Qtrs
Loss on change in fair value of convertible notes payable	`LossOnChangeInFairValueOfConvertibleNotesPayable`	$423.00K	USD	3 Qtrs
Non-cash reduction of deferred income upon exercise of option liability	`NoncashReductionOfDeferredIncomeUponExerciseOfOptionLiability`	-	USD	3 Qtrs
Non-cash reduction of deferred income upon exercise of option liability	`NoncashReductionOfDeferredIncomeUponExerciseOfOptionLiability`	$1.48M	USD	3 Qtrs
Interest expense on convertible promissory note	`InterestExpenseOnConvertiblePromissoryNotePayable`	$86.00K	USD	3 Qtrs
Interest expense on convertible promissory note	`InterestExpenseOnConvertiblePromissoryNotePayable`	-	USD	3 Qtrs
Gain on warrant remeasurement	`GainOnWarrantRemeasurement`	-	USD	3 Qtrs
Gain on warrant remeasurement	`GainOnWarrantRemeasurement`	$131.00K	USD	3 Qtrs
Stock-based compensation expense	`ShareBasedCompensation`	$10.00K	USD	3 Qtrs
Stock-based compensation expense	`ShareBasedCompensation`	-	USD	3 Qtrs
Non-cash interest expense	`NoncashInterestExpense`	$8.00K	USD	3 Qtrs
Non-cash interest expense	`NoncashInterestExpense`	-	USD	3 Qtrs
Amortization of financed Directors and Officers insurance	`AdjustmentForAmortization`	-	USD	3 Qtrs
Amortization of financed Directors and Officers insurance	`AdjustmentForAmortization`	$44.00K	USD	3 Qtrs
Prepaid expenses and other current assets	`IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets`	$-93.00K	USD	3 Qtrs
Prepaid expenses and other current assets	`IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets`	-	USD	3 Qtrs
Accounts payable	`IncreaseDecreaseInAccountsPayable`	-	USD	3 Qtrs
Accounts payable	`IncreaseDecreaseInAccountsPayable`	$6.00K	USD	3 Qtrs
Accrued expenses and other current liabilities	`IncreaseDecreaseInAccruedExpensesAndOtherCurrentLiabilities`	$-105.00K	USD	3 Qtrs
Accrued expenses and other current liabilities	`IncreaseDecreaseInAccruedExpensesAndOtherCurrentLiabilities`	$-1.60M	USD	3 Qtrs
Intangible assets	`IncreaseDecreaseInIntangibleAssetsCurrent`	$5.00K	USD	3 Qtrs
Intangible assets	`IncreaseDecreaseInIntangibleAssetsCurrent`	-	USD	3 Qtrs
Net cash flows from operating activities	`NetCashProvidedByUsedInOperatingActivities`	$-1.39M	USD	3 Qtrs
Net cash flows from operating activities	`NetCashProvidedByUsedInOperatingActivities`	$-2.92M	USD	3 Qtrs
Issuance of loan - related party	`PaymentsToFundLongtermLoansToRelatedParties`	$129.00K	USD	3 Qtrs
Issuance of loan - related party	`PaymentsToFundLongtermLoansToRelatedParties`	$357.00K	USD	3 Qtrs
Proceeds from loan repayment - related party	`ProceedsFromLoanRepaymentRelatedParty`	$585.00K	USD	3 Qtrs
Proceeds from loan repayment - related party	`ProceedsFromLoanRepaymentRelatedParty`	-	USD	3 Qtrs
Net cash flows from investing activities	`NetCashProvidedByUsedInInvestingActivities`	$228.00K	USD	3 Qtrs
Net cash flows from investing activities	`NetCashProvidedByUsedInInvestingActivities`	$-129.00K	USD	3 Qtrs
Proceeds from Merger and related PIPE Financing, net of transaction costs	`ProceedsFromMergerAndRelatedPipeFinancingNetOfTransactionCosts`	$8.49M	USD	3 Qtrs
Proceeds from Merger and related PIPE Financing, net of transaction costs	`ProceedsFromMergerAndRelatedPipeFinancingNetOfTransactionCosts`	-	USD	3 Qtrs
Proceeds from issuance of option	`ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans`	$498.00K	USD	3 Qtrs
Proceeds from issuance of option	`ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans`	-	USD	3 Qtrs
Proceeds from the issuance of notes payable	`ProceedsFromNotesPayable`	-	USD	3 Qtrs
Proceeds from the issuance of notes payable	`ProceedsFromNotesPayable`	$182.00K	USD	3 Qtrs
Capital contribution - related party	`ProceedsFromIssuanceOfCommonStock`	$151.00K	USD	3 Qtrs
Capital contribution - related party	`ProceedsFromIssuanceOfCommonStock`	-	USD	3 Qtrs
Proceeds from issuance of convertible notes payable, carried at fair value	`ProceedsFromIssuanceOfConvertibleNotesPayableCarriedAtFairValue`	$503.00K	USD	3 Qtrs
Proceeds from issuance of convertible notes payable, carried at fair value	`ProceedsFromIssuanceOfConvertibleNotesPayableCarriedAtFairValue`	$1.47M	USD	3 Qtrs
Proceeds from issuance of convertible promissory note payable, carried at cost	`ProceedsFromConvertibleDebt`	$813.00K	USD	3 Qtrs
Proceeds from issuance of convertible promissory note payable, carried at cost	`ProceedsFromConvertibleDebt`	-	USD	3 Qtrs
Interest paid on convertible promissory note, carried at cost	`InterestPaidOnConvertiblePromissoryNoteCarriedAtCost`	-	USD	3 Qtrs
Interest paid on convertible promissory note, carried at cost	`InterestPaidOnConvertiblePromissoryNoteCarriedAtCost`	$81.00K	USD	3 Qtrs
Proceeds from sale of equity securities	`ProceedsFromIssuanceOrSaleOfEquity`	-	USD	3 Qtrs
Proceeds from sale of equity securities	`ProceedsFromIssuanceOrSaleOfEquity`	$830.00K	USD	3 Qtrs
Net cash flows from financing activities	`NetCashProvidedByUsedInFinancingActivities`	$11.34M	USD	3 Qtrs
Net cash flows from financing activities	`NetCashProvidedByUsedInFinancingActivities`	$1.51M	USD	3 Qtrs
Net change in cash and cash equivalents before effect of exchange rate changes	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect`	-	USD	3 Qtrs
Net change in cash and cash equivalents before effect of exchange rate changes	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect`	$8.65M	USD	3 Qtrs
Effect of exchange rate changes on cash and cash equivalents	`EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations`	-	USD	3 Qtrs
Effect of exchange rate changes on cash and cash equivalents	`EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations`	$-5.00K	USD	3 Qtrs
Net change in cash	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect`	$8.64M	USD	3 Qtrs
Net change in cash	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect`	-	USD	3 Qtrs
Cash and cash equivalents at beginning of period	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations`	-	USD	Point-in-time
Cash and cash equivalents at beginning of period	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations`	-	USD	Point-in-time
Cash and cash equivalents at beginning of period	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations`	$8.64M	USD	Point-in-time
Cash and cash equivalents at beginning of period	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations`	-	USD	Point-in-time
Cash and cash equivalents at end of period	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations`	-	USD	Point-in-time
Cash and cash equivalents at end of period	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations`	-	USD	Point-in-time
Cash and cash equivalents at end of period	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations`	$8.64M	USD	Point-in-time
Cash and cash equivalents at end of period	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations`	-	USD	Point-in-time
Issuance of Conduit Pharmaceuticals Inc. common stock to Cizzle Biotechnology Holding PLC upon exercise of option	`IssuanceOfConduitPharmaceuticalsInc.CommonStockToCizzleBiotechnologyHoldingPlc`	-	USD	3 Qtrs
Issuance of Conduit Pharmaceuticals Inc. common stock to Cizzle Biotechnology Holding PLC upon exercise of option	`IssuanceOfConduitPharmaceuticalsInc.CommonStockToCizzleBiotechnologyHoldingPlc`	$151.00K	USD	3 Qtrs
Exchange of Conduit Pharmaceuticals Limited convertible notes for shares of Conduit Pharmaceuticals Inc. common stock in connection with the Merger	`ExchangeOfConduitPharmaceuticalsLimitedConvertibleNotesForSharesOfConduitPharmaceuticalsInc.CommonStockInConnectionWithMerger`	$3.69M	USD	3 Qtrs
Exchange of Conduit Pharmaceuticals Limited convertible notes for shares of Conduit Pharmaceuticals Inc. common stock in connection with the Merger	`ExchangeOfConduitPharmaceuticalsLimitedConvertibleNotesForSharesOfConduitPharmaceuticalsInc.CommonStockInConnectionWithMerger`	-	USD	3 Qtrs
Accrued transaction costs	`AccruedTransactionCosts`	-	USD	3 Qtrs
Accrued transaction costs	`AccruedTransactionCosts`	$5.74M	USD	3 Qtrs
Non-cash directors and officers insurance	`NoncashDirectorsAndOfficersInsurance`	$1.07M	USD	3 Qtrs
Non-cash directors and officers insurance	`NoncashDirectorsAndOfficersInsurance`	-	USD	3 Qtrs
Net Liabilities assumed in the Merger	`NoncashMergerFinancing`	$6.12M	USD	3 Qtrs
Net Liabilities assumed in the Merger	`NoncashMergerFinancing`	-	USD	3 Qtrs
Initial value of warrant liabilities issued in connection with PIPE Financing and Closing of the Merger	`InitialValueOfWarrantLiabilitiesIssuedInConnectionWithPipeFinancingAndClosingOfMerger`	-	USD	3 Qtrs
Initial value of warrant liabilities issued in connection with PIPE Financing and Closing of the Merger	`InitialValueOfWarrantLiabilitiesIssuedInConnectionWithPipeFinancingAndClosingOfMerger`	$223.00K	USD	3 Qtrs
Fair value of shares received and receivable related to the sale of future revenue	`FairValueOfSharesReceivedAndReceivableRelatedToSaleOfFutureRevenue`	$1.28M	USD	3 Qtrs
Fair value of shares received and receivable related to the sale of future revenue	`FairValueOfSharesReceivedAndReceivableRelatedToSaleOfFutureRevenue`	-	USD	3 Qtrs

Stockholders Equity 58 line items

Line Item	Tag	Value	Unit	Period
Balance	`StockholdersEquity`	$-10.09M	USD	Point-in-time
Balance	`StockholdersEquity`	$-6.14M	USD	Point-in-time
Balance	`StockholdersEquity`	$-15.04M	USD	Point-in-time
Balance	`StockholdersEquity`	$-1.08M	USD	Point-in-time
Balance	`StockholdersEquity`	$-5.94M	USD	Point-in-time
Balance	`StockholdersEquity`	$-6.49M	USD	Point-in-time
Retroactive application of Merger	`StockholdersEquityRetroactiveApplicationOfMerger`	-	USD	Point-in-time
Retroactive application of Merger	`StockholdersEquityRetroactiveApplicationOfMerger`	-	USD	Point-in-time
Retroactive application of Merger	`StockholdersEquityRetroactiveApplicationOfMerger`	-	USD	Point-in-time
Retroactive application of Merger	`StockholdersEquityRetroactiveApplicationOfMerger`	-	USD	Point-in-time
Adjusted Balances, beginning of period	`StockholdersEquityAdjusted`	$-15.04M	USD	Point-in-time
Adjusted Balances, beginning of period	`StockholdersEquityAdjusted`	$-10.09M	USD	Point-in-time
Adjusted Balances, beginning of period	`StockholdersEquityAdjusted`	$-6.14M	USD	Point-in-time
Adjusted Balances, beginning of period	`StockholdersEquityAdjusted`	$-5.94M	USD	Point-in-time
Reclassification of additional paid-in-capital	`AdjustmentsToAdditionalPaidInCapitalOther`	-	USD	3 Qtrs
Reclassification of additional paid-in-capital	`AdjustmentsToAdditionalPaidInCapitalOther`	-	USD	3 Qtrs
Reclassification of additional paid-in-capital	`AdjustmentsToAdditionalPaidInCapitalOther`	-	USD	1 Quarter
Reclassification of additional paid-in-capital	`AdjustmentsToAdditionalPaidInCapitalOther`	-	USD	1 Quarter
Foreign currency translation adjustment	`OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent`	$36.00K	USD	3 Qtrs
Foreign currency translation adjustment	`OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent`	$610.00K	USD	1 Quarter
Foreign currency translation adjustment	`OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent`	$608.00K	USD	1 Quarter
Foreign currency translation adjustment	`OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent`	$1.27M	USD	3 Qtrs
Net income (loss)	`NetIncomeLoss`	$-2.31M	USD	3 Qtrs
Net income (loss)	`NetIncomeLoss`	$-956.00K	USD	1 Quarter
Net income (loss)	`NetIncomeLoss`	$-1.82M	USD	3 Qtrs
Net income (loss)	`NetIncomeLoss`	$1.99M	USD	1 Quarter
Reclassification of additional paid-in capital**	`AdjustmentsToAdditionalPaidInCapitalOther`	-	USD	1 Quarter
Reclassification of additional paid-in capital**	`AdjustmentsToAdditionalPaidInCapitalOther`	-	USD	1 Quarter
Reclassification of additional paid-in capital**	`AdjustmentsToAdditionalPaidInCapitalOther`	-	USD	3 Qtrs
Reclassification of additional paid-in capital**	`AdjustmentsToAdditionalPaidInCapitalOther`	-	USD	3 Qtrs
Issuance of Conduit Pharmaceuticals Inc. common stock to holders of Conduit Pharmaceuticals Limited convertible notes on the Closing Date (Note 3)	`StockIssuedDuringPeriodValueConversionOfConvertibleSecurities`	$3.69M	USD	3 Qtrs
Issuance of Conduit Pharmaceuticals Inc. common stock to holders of Conduit Pharmaceuticals Limited convertible notes on the Closing Date (Note 3)	`StockIssuedDuringPeriodValueConversionOfConvertibleSecurities`	$3.69M	USD	1 Quarter
Issuance of Conduit Pharmaceuticals Inc. common stock to holders of Conduit Pharmaceuticals Limited convertible notes on the Closing Date, shares	`StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities`	373,570.00	shares	3 Qtrs
Merger, net of redemptions (Note 3)	`StockIssuedDuringPeriodValueAcquisitions`	$13.56M	USD	1 Quarter
Merger, net of redemptions (Note 3)	`StockIssuedDuringPeriodValueAcquisitions`	$13.56M	USD	3 Qtrs
Issuance of Conduit Pharmaceuticals Inc. common stock in connection with PIPE Financing (Note 3)	`StockIssuedDuringPeriodValueNewIssues`	$19.78M	USD	3 Qtrs
Issuance of Conduit Pharmaceuticals Inc. common stock in connection with PIPE Financing (Note 3)	`StockIssuedDuringPeriodValueNewIssues`	$19.78M	USD	1 Quarter
Issuance of Conduit Pharmaceuticals Inc. common stock to Cizzle Biotechnology Holding PLC	`StockIssuedDuringPeriodValuePurchaseOfRevenue`	$151.00K	USD	3 Qtrs
Issuance of Conduit Pharmaceuticals Inc. common stock to Cizzle Biotechnology Holding PLC	`StockIssuedDuringPeriodValuePurchaseOfRevenue`	$151.00K	USD	1 Quarter
Issuance of Conduit Pharmaceuticals Inc. common stock to an advisor for services directly related to the Merger (Note 3)	`StockIssuedDuringPeriodValueIssuedForServices`	-	USD	1 Quarter
Issuance of Conduit Pharmaceuticals Inc. common stock to an advisor for services directly related to the Merger (Note 3)	`StockIssuedDuringPeriodValueIssuedForServices`	-	USD	3 Qtrs
Reduction of excise tax liability associated with the Merger (Note 3)	`AdjustmentsToAdditionalPaidInCapitalReductionOfExciseTaxLiabilityAssociatedWithMerger`	$1.14M	USD	1 Quarter
Reduction of excise tax liability associated with the Merger (Note 3)	`AdjustmentsToAdditionalPaidInCapitalReductionOfExciseTaxLiabilityAssociatedWithMerger`	$1.14M	USD	3 Qtrs
Capital contribution - related party	`AdjustmentsToAdditionalPaidInCapitalContributionRelatedParty`	$150.00K	USD	3 Qtrs
Capital contribution - related party	`AdjustmentsToAdditionalPaidInCapitalContributionRelatedParty`	$150.00K	USD	1 Quarter
Stock-based compensation	`AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue`	$10.00K	USD	1 Quarter
Stock-based compensation	`AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue`	$10.00K	USD	3 Qtrs
Reclassification of additional paid-in-capital	`ReclassificationOfAdditionalPaidincapitalBeforeAdjusted`	-	USD	3 Qtrs
Foreign currency translation adjustment	`OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent`	$36.00K	USD	3 Qtrs
Foreign currency translation adjustment	`OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent`	$610.00K	USD	1 Quarter
Foreign currency translation adjustment	`OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent`	$608.00K	USD	1 Quarter
Foreign currency translation adjustment	`OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent`	$1.27M	USD	3 Qtrs
Balance	`StockholdersEquity`	$-1.08M	USD	Point-in-time
Balance	`StockholdersEquity`	$-15.04M	USD	Point-in-time
Balance	`StockholdersEquity`	$-5.94M	USD	Point-in-time
Balance	`StockholdersEquity`	$-10.09M	USD	Point-in-time
Balance	`StockholdersEquity`	$-6.14M	USD	Point-in-time
Balance	`StockholdersEquity`	$-6.49M	USD	Point-in-time

Data is extracted from SEC EDGAR XBRL filings. Values shown are as reported in the filing.